Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00094835 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Panitumumab
DRUG: Motesanib diphosphate
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Amgen